AFT Pharmaceuticals - FDA Pain Is Over
AFT Pharmaceuticals (AFT) has finally received the long awaited US FDA approval for its Maxigesic IV product (hospital-based product)
354 Views
AFT Pharmaceuticals: FY23 Result — On Script
We liked what we saw in AFT Pharmaceuticals' (AFT) FY23 result: (1) ANZ revenue (AFT's core defensive growth driver) grew +24% versus FY22, (2)...
346 Views
AFT Pharmaceuticals (AFT): FY23 Result – First Impressions
AFT Pharmaceuticals (AFT) reported an operating FY23 result in-line with guidance and slightly ahead of our expectations with EBIT ex licensing...
340 Views
AFT Pharmaceuticals: FY23 Preview — Story Remains Intact
We expect AFT Pharmaceuticals' (AFT) underlying FY23 result to show strong growth, led by its Australia and New Zealand segments, when it reports...
212 Views
AFT Pharmaceuticals: Breaking the Pain Barrier
AFT Pharmaceuticals' (AFT) notification of US FDA approval for its rapid release tablet form of Maxigesic provides a material long-term opportunity.
275 Views